Danaher (DHR) Q2 2026 (USD): EPS 1.94 (exp. 1.84), Revenue 6.3bln (exp. 6.11bln)
Danaher beat Q2 expectations and raised its FY26 EPS guidance, highlighted by mid-teens bioprocessing order growth and the strongest Life Sciences performance in years, signaling a sector recovery.
News detail
Other Metrics (USD): Diagnostics Revenue 2.47bln (exp. 2.34bln) Life Sciences Revenue 1.88bln (exp. 1.8bln) Biotech Revenue 1.92bln (exp. 1.96bln) COMMENTARY:CEO Rainer Blair says Danaher delivered a better-than-expected Q2, with core growth improving versus Q1 and disciplined execution driving high-single-digit adjusted EPS growth, while Life Sciences delivered its strongest quarter in several years and bioprocessing orders grew mid-teens.GUIDANCE: Sees Q3 core revenue growth between 2.0-3.0% Y/Y, and adj. operating profit margin of about 26.5%. Raises FY26 guidance; sees FY adj. EPS between USD 8.45-8.60 (exp. 8.45; prev. saw saw 8.35-8.55)
Related stocks
1 stocksWhat do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.